The collaboration aims to facilitate KateTx's initial internal portfolio of gene therapy programmes focused on muscle and heart diseases


Capsida, Kate Therapeutics partner to produce KateTx's gene therapies. (Credit: THAVIS 3D on Unsplash)

Capsida Biotherapeutics and Kate Therapeutics have entered into a strategic partnership to tap into Capsida’s proficiency in adeno-associated virus (AAV) manufacturing.

The collaboration aims to facilitate KateTx’s initial internal portfolio of gene therapy programmes focused on muscle and heart diseases. Capsida will take on the responsibility of Good Manufacturing Practice (GMP) manufacturing for KateTx’s gene therapies as they progress through preclinical and clinical development.

In return, Capsida will receive undisclosed funding over the duration of the agreement.

KateTx’s disclosed internal programs include gene therapies for conditions like myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy, both significant contributors to adult-onset muscular dystrophy.

Capsida Biotherapeutics CEO Peter Anastasiou said: “Capsida possesses end-to-end expertise – which includes AAV capsid engineering, preclinical, clinical, and state-of-the-art manufacturing.

“We are thrilled to be able to leverage our established capabilities in AAV manufacturing and support a peer company to reach patients in a complementary space, while continuing to advance our own internal and partnered pipeline in CNS and ophthalmology.”

Kate Therapeutics president and CEO Kevin Forrest said: “KateTx is leading the way in developing capsid and cargo combinations to address muscle and heart diseases in ways that have not been previously possible.

“Capsida’s exceptional AAV manufacturing capabilities allow us to build our pipeline, de-risk our programs, and advance them into the clinic in the most rapid manner possible, so we can bring much-needed therapies to patients quickly.”

Capsida Biotherapeutics is engaged in developing treatments for rare and common diseases across all ages. The company’s new class of engineered adeno associated virus (AAV)-based delivery technologies enables a wide range of therapeutic modalities, including DNA, RNA, gene editors, vectorized antibodies and other genetic cargoes.

Kate Therapeutics (KateTx) is a biotechnology company focused on developing transformative therapies for neuromuscular and genetic diseases.

KateTx’s mission is to develop safe and effective gene therapies that address the underlying genetic causes of these diseases, providing hope and improved quality of life for patients and their families.